DDInter38 DDInter1747
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Interferon alfa-n1
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Aldesleukin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfa-n1